COMPASS Pathways (CMPS) Stock Price, News, Quotes-Moomoo

English
中文繁體
中文简体

Download

Mobile

Moomoo Desktop

The next-gen workspace

Download now

Click to view more download content

English
中文繁體
中文简体

Dark
Light

Open Account

Download

US Stock MarketDetailed Quotes

CMPS COMPASS Pathways

Watchlist

4.595
+0.035+0.77%

Close Nov 29 13:00 ET

4.600
+0.005+0.11%

Post 16:49 ET

314.39MMarket Cap-2107P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Compass Pathways to Participate in December Investor Conferences
BusinesswireNov 25 16:00 ET
COMPASS Pathways: Institutional Pressure Amid $43M Market Cap Decline, What's Next For This Psychedelics Co?
BenzingaNov 25 14:50 ET
European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday
MT NewswiresNov 21 11:20 ET
Despegar.com, Zai Lab, Bloom Energy And Other Big Stocks Moving Higher On Friday
BenzingaNov 15 10:12 ET
Express News | U.S.-Listed Shares of ATAI Life Sciences up 9.1%
ReutersNov 15 09:34 ET
Express News | GH Research Shares up 4.1%
ReutersNov 15 09:33 ET

Comments

IDKWTFIMDOING

Jul 22 04:21

$COMPASS Pathways (CMPS.US)$
https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs

Jaguar8

May 8 05:31

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways announces durable improvement in symptoms through 12 weeks in open-label phase 2 study of COMP360 psilocybin in post-traumatic stress disorder

Jaguar8

May 2 06:00

$COMPASS Pathways (CMPS.US)$
NEWS
Compass Pathways establishes research collaboration with Mindful Health Solutions to inform the development of a scalable and cost-effective delivery model for investigational COMP360 psilocybin treatment

Moomoo AI

Jan 3 10:34

Cody Shandraw of Ambria Capital suggests FDA approval for MDMA legalization could be imminent, asserting that MDMA therapy might follow a similar trajectory to JNJ's Spravato treatment for depression. He is thrilled about the potential coverage of the therapy by the U.S. Department of Veterans Affairs for military personnel.